Sarepta Therapeutics Inc. (DE) News

Latest updates and market news for SRPT

6 news

Nov 25 - Dec 1, 2025

Page 1

How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?

Simply Wall St.

3 days ago

How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Business Wire

6 days ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Trump Media Stock and 11 More Tax-Loss Victims to Avoid Until 2026

Barrons.com

6 days ago

Trump Media Stock and 11 More Tax-Loss Victims to Avoid Until 2026

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

Zacks

6 days ago

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

MT Newswires

6 days ago

Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy

📊

AI Sentiment

Positive

7/10

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Business Wire

6 days ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Share this news page

Share on Social Networks: